Influenza Diagnostic Market

Influenza Diagnostic Market Outlook (2024 to 2034)

The global influenza diagnostic market is estimated to be valued at US$ 1,806.5 million in 2024 and is forecast to reach a value of US$ 3,336.9 million by 2034, with a projected CAGR of 6.3% from 2024 to 2034. The rising emphasis on early detection for effective influenza management is fueling the growth of the influenza diagnostic market.

Post-pandemic, the general population has become increasingly aware of health and personal care. This has elevated the demand for effective influenza management treatments in the medical sector, especially in countries where the medical infrastructure is well-developed. The booming pharmaceutical industry is also considered one of the major drivers for the market growth for influenza diagnostic treatments.

The rising incidence of influenza is another significant contributor to market growth. Over the years, there has been an influx of evolving and new strains of viruses. This leads to a continuous need for effective diagnostic tools to track and manage outbreaks and identify specific influenza strains, allowing for targeted and timely interventions.

Besides this, advancements in diagnostic technologies also play a pivotal role in the market's expansion. In the long run, innovations in molecular diagnostics, rapid antigen tests, and other diagnostic methods have improved the efficiency and accuracy of influenza testing. These advancements have enhanced diagnostic capabilities and expanded the market by attracting healthcare providers and facilities to adopt these solutions.

The influenza diagnostic market generated an estimated revenue of US$ 1,356.9 million in 2019. From 2019 to 2023, the market grew at a pace of 5.89% CAGR and added a staggering revenue of US$ 449.6 million.

Report Attributes	Details
Estimated Market Value (2024E)	US$ 1,806.5 million
Forecasted Market Value (2034F)	US$ 3,336.9 million
Global Market Growth Rate (2024 to 2034)	6.30% CAGR
Traditional Diagnostic Tests Segment Growth Rate (2024 to 2034)	66.70%
Hospital Segment Growth Rate (2024 to 2034)	54.40%
North America Market Share (2024)	37.20%
East Asia Market Share (2024)	12.60%
Key Companies Profiled	Thermo Fisher Scientific Hologic Quidel Corporation F. Hoffmann-La Roche AG Abbott Laboratories Becton Dickinson and Company Danaher Corporation Meridian Bioscience bioMérieux SA Luminex Corporation Siemens Healthineers AG GenMark Diagnostics Sekisui Diagnostics LLC Altona Diagnostics GmbH SA Scientific ELITech Group Coris Bioconcept SPRL Mast Group Ltd.

Which Factors are Driving the Global Surge in Influenza Diagnostic Demand?

“Rising Incidences of Influenza to Complement Market Growth”

Rising incidences of influenza have propelled the growth of the influenza diagnostic market. This has also inspired governments to prioritize public health measures, allocate resources, and implement comprehensive strategies to address the significant impact of influenza on their populations. Healthcare entities, both public and private, are investing millions of dollars in improving influenza diagnostic treatments by investing in research and development initiatives.

“Technological Advancements in Influenza Diagnostics to Amplify Market Growth”

Technological advancements drive growth in the influenza diagnostic industry. These innovations have played a pivotal role in improving the speed, accuracy, and effectiveness of detecting and managing influenza cases. This has generated immense trust and reliability in the general population for influenza diagnostic treatments, subsequently aiding the influenza diagnostic market growth.

The demand for influenza diagnostic solutions is also skyrocketing due to the speed at which influenza can be diagnosed using these techniques. Technological advancements have also enabled healthcare facilities to set up temporary testing camps in diverse settings, including remote areas, emergency departments, and clinics. This widespread availability has also contributed positively to the overall market.

What is Hindering the Expansion of the Influenza Diagnostic Market?

“Seasonal Nature of Influenza, Vaccine Efficacy, and Healthcare Infrastructure Disparities to Slow down Market Growth”

One of the significant restraints slowing down market growth for influenza diagnostics is the seasonal nature of influenza. This leads to fluctuations in the demand for diagnostic tests. Also, influenza diagnostics face a bolstering demand in flu seasons, which then reduces during non-peak periods. This uncertainty significantly hampers the influenza diagnostic market in the long run.

Disparities in healthcare infrastructure, especially in underdeveloped and developing regions, also limit the widespread adoption of advanced diagnostic technologies. All these factors restrict the market’s growth.

Country-wise Insights

The North American influenza diagnostic market is poised for exceptional growth, projecting an average CAGR of 6.40% through 2034. The surge is primarily attributed to increasing demand for influenza diagnostics in key countries, notably the United States and Mexico. The United States dominates the influenza diagnostic industry with an estimated 87.70% market share in 2024.

The East Asian influenza diagnostic market is anticipated to exhibit substantial progress, aiming for a 6.60% CAGR in 2024. In this region, Japan emerges as the key player in the industry, commanding a significant share of 45.10% in 2024.

Why is the United States Leading the Influenza Diagnostic Market in the North American Region?

“Robust Healthcare Infrastructure and Research and Development Initiatives in the United States”

Atteibutes	Details
CAGR (2024 to 2034)	6.4%

The North American market stood at US$ 671 million in 2024, acquiring a revenue share of 37.20%, and is further projected to expand at a CAGR of 6.40% through 2034. The United States influenza diagnostic industry is estimated to be worth US$ 589 million in 2024. The demand for influenza diagnostics in the United States is projected to rise at a CAGR of 6.4% through 2034.

The United States is blessed with several drivers, making it the leading country in the influenza diagnostic market. The country has one of the most advanced and sophisticated healthcare ecosystems, with progressive medical facilities, laboratories, and diagnostic centers. This supports the widespread adoption of innovative influenza diagnostic technologies, thus aiding market growth. Besides this, the country is also a hub for research and development in the healthcare and pharmaceutical sectors. This has positioned the United States as one of the leading countries in the global influenza diagnostic market.

Which Country Commands a Significant Share of the East Asian Influenza Diagnostic Market?

“Technological Innovations and Government Commitment to Healthcare in Japan”

Attributes	Details
CAGR (2024 to 2034)	6.1%

The Japanese influenza diagnostic industry is estimated to be worth US$ 102 million in 2024, garnering a significant share of 45.1% of the East Asian market. Sales of influenza diagnostic kits are predicted to record a CAGR of 6.1% through 2034.

Japan has advanced healthcare facilities, which is driving the market growth. Besides this, the Japanese government also exhibits a strong commitment to healthcare. This has inspired them to invest massively in influenza diagnostic laboratories, testing camps, and temporary testing facilities, thus augmenting influenza diagnostic market share.

Category-wise Insights

Based on the test type, the traditional diagnostic tests segment is estimated to hold a 66.70% market share in 2024. Simultaneously, the molecular diagnostic tests segment is anticipated to secure a 33.30% share, contributing significantly to the market's resource diversity and stability.

Based on the end user, the hospital segment marks its dominance in the influenza diagnostic industry, with a share of 54.40% in 2024.

Which End User Widely Employs Influenza Diagnostic Solutions?

“Hospitals and Clinical Laboratories Drive the Demand for Influenza Diagnostic Solutions”

Attribute	Detail
Market Share in 2024	54.40%

Hospitals and clinical labs are the leading end-users of influenza diagnostic solutions. Demand for these methodologies is rising to swiftly and accurately identify influenza cases among patients with respiratory symptoms. In addition to this, their popularity is rising as they initiate timely and appropriate treatment strategies, reducing the illness's severity.

Rapid and accurate diagnostic solutions contribute to the early identification of influenza cases, aiding in the implementation of preventive measures that minimize the risk of hospital-acquired infections among patients and healthcare workers.

Competitive Landscape

The influenza diagnostics industry consists of multiple players operating at different levels. Some of the key players include Becton, Abbott Laboratories, F. Hoffmann-La Roche AG, Quidel Corporation, Hologic, Thermo Fisher Scientific, and others.

Key players work on creating myriads of advanced influenza diagnostic treatments and solutions. Hospitals, diagnostic laboratories, research and academic institutes, and contract research organizations rely on these companies for influenza diagnostic solutions and technologies. Smaller companies, too, exist in the market with a limited consumer base and marketing capabilities. These companies generally rely on the innovations of industry giants to implement new technologies in their products.

Recent Developments

• In November 2023, Mylab and Ekincare collaborated to promote NASOVAC-S4, an influenza nasal vaccine. Administered non-invasively and painlessly through the nasal route, it becomes an attractive option for business employee wellness programs.

• In November 2023, researchers at the Gwangju Institute of Science and Technology developed metal-enhanced fluorescence probes for influenza A virus detection. The lateral flow immunosensor, incorporating these probes, enabled speedy, accurate, cost-effective, and highly sensitive molecular diagnosis. The technology could detect the virus in under 20 minutes.

• In January 2023, Roche announced the European Commission’s approval of Xofluza for the treatment and prevention of influenza in children aged one year and older. It is the first influenza antiviral with a new mechanism of action in almost 20 years, stopping viral replication faster than oseltamivir.

Key Segments Covered in Influenza Diagnostic Industry Research

• By Test :

  • Traditional Influenza Diagnostic Tests
    • Rapid Influenza Diagnostic Tests (RIDTs)
    • Direct Fluorescent Antibody (DFA) Tests
    • Viral Culture
    • Serological Assays
  • Molecular Influenza Diagnostic Tests
    • Reverse Transcription Polymerase Chain Reaction (RT-PCR)
    • Isothermal Nucleic Acid Amplification Tests (INAAT)
    • Loop-Mediated Isothermal-based Amplification Assays
    • Transcription Mediated Isothermal-based Amplification Assays
    • Transcription Mediated Isothermal-based Amplification Assays

• By End User :

  • Hospitals and Clinical Laboratories
  • Diagnostic Reference Laboratories
  • Academic/Research Institutes

• By Region :

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)